Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease

Clinical Neuropharmacology

Volumn 22, Issue 5, 1999, Pages 301-305

  Künig, Gabriella ^a   Pogarell, Oliver ^a,b   Möller, J Carsten ^a,b   Delf, Martin ^a   Oertel, Wolfgang H ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Parkinson's disease; Pramipexole; Rest tremor

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; LEVODOPA; PLACEBO; PRAMIPEXOLE;

ADULT; AGED; AKINESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RIGIDITY; TREMOR;

AGED; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOPAMINE AGONISTS; HUMANS; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREATMENT OUTCOME; TREMOR;

EID: 0345425689     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Oertel WH, Dodel RC. International guide to drugs for Parkinson's disease. Mov Disord 1995;10:121-31.
2. Oertel WH, Quinn N. Parkinsonism. In: Brandt T, Diener HC, Caplan LR, Kennard C, Dichgans J, eds. Neurological disorders: course and treatment. San Diego, CA: Academic Press; 1996:715-72.
3. Marsden CD. Parkinson's disease. Lancet 1990;335:948-52.
4. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993; 329:1021-7.
5. Sadeh M, Braham J, Modan M. Effects of anticholinergic drugs on memory in Parkinson's disease. Arch Neurol 1982;39:666-7.
6. De Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y. Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:1161-4.
7. Van Herwaarden G, Berger HJ, Horstink MW. Short term memory in Parkinson's disease after withdrawal of long term anticholinergic therapy. Clin Neuropharmacol 1993;16:438-43.
8. Stern MB. The changing standard of care in Parkinson's disease: current concepts and controversies. Neurology 1997;49(suppl 1): 1-7.
9. Mierau J, Bechtel WD: SND 919 inhibits dopamine release in vivo and in vitro [abstract]. Psychopharmacology 1988;96:338.
10. 2 receptor agonist. Eur J Pharmacol 1992;215:161-70.
11. Robertson GS, Tham CS, Wilson C, Jakubovic A, Fibiger HC. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther 1993; 264:1344-51.
12. Kreiss DS, Bergstrom BA, Gonzalez AM, Huang KX, Sibley DR, Walters JR. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol 1995;277:209-14.
13. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-47.
14. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-ranging study. JAMA 1997; 278:125-30.
15. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine agonist, in advanced Parkinson's disease. J Neural Transm 1995;45:225-30.
16. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49: 162-8.
17. Pogarell O, Künig G, Oertel WH. A non-ergot dopamine agonist, pramipexole, in the therapy of advanced Parkinson's disease: improvement of parkinsonian symptoms and treatment-associated complications - a review of three studies. Clin Neuropharmacol 1997;20(suppl 1):28-35.
18. Guttman M, International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptin treatment with placebo in advanced Parkinson's disease. Neurology 1997;49:1060-5.
19. Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-8.
20. Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520-5.
21. Factor SA, Sanchez-Ramos JR, Weiner WJ. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 1988;51:529-33.
22. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-7.
23. Laihinen A, Rinne UK, Suchy I. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease. Acta Neurol Scand 1992;86:593-5.
24. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease. Neurology; 1997;49: 162-8.